A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 148 participants.

Also called NCT02851849

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 148 participants (enrolled count) (from the registry)
Sponsor
Ligand Pharmaceuticals (from the registry)
Registry
  • NCT NCT02851849
Other papers using this trial's data
  • Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study Diabetes care, 2020-01 DOI, PubMed 31694861

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02851849. Randomized; double masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2017-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
LGD-6972-5 mg
Intervention (Drug)
LGD-6972-10 mg
Intervention (Drug)
LGD-6972-15 mg
Intervention (Other)
Placebo
Lead sponsor
Ligand Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02851849
Content hash
ffb30537cca95876b71cd06ce01efe9801ca186e17bcb161de57870241827559